KPTI News and Press, Karyopharm Therapeutics Inc. From 08/05/21

Karyopharm Reports Business Highlights and Second Quarter 2021 Financial Results -- Achieved Second Quarter 2021 XPOVIO® (selinexor) Net Product Revenues of $20.2 Million and $41.9 Million YTD, Up 8% Versus Second Quarter 2020 and Up 21% Versus First Half of 2020 -- -- ...

Karyopharm Therapeutics' (NASDAQ:KPTI) partner Antengene announces that through a priority review process, the South Korean Ministry of Food and Drug Safety has approved its New Drug Application (NDA) for the Orphan Drug-designated oral inhibitor of XPO1, selinexor (XPOVIO...

Karyopharm to Report Second Quarter 2021 Financial Results on August 5, 2021 -- Conference Call Scheduled for Thursday, August 5, 2021, at 8:30 a.m. ET -- PR Newswire NEWTON, Mass. , July 29, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPT...

Karyopharm Announces Dosing of First Patients in Two New Company-Sponsored Clinical Studies in Melanoma and Myelofibrosis PR Newswire NEWTON, Mass. , July 28, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ: KPTI), a commercial-stage pharmaceutical comp...

At the mid-year mark, our contributors give updates on their picks. We highlight two recent top performers. And stay tuned for next week, where some contributors introduce new ideas with the Double Down or Diversify series. For further details see: SA Marketplace 2021 To...

Karyopharm Therapeutics' (KPTI) partner Antengene has submitted a New Drug Application ((NDA)) to the Taiwan Food and Drug Administration for selinexor, a XPO1 inhibitor, for three indications:In combination with bortezomib and dexamethasone (XVd), or in combination with dexamethaso...

Alex Potemkin/iStock Unreleased via Getty Images Sensei downgraded, price trimmed on program discontinuation Oppenheimer has downgraded shares of Sensei Biotherapeutics (SNSE) from outperform to perform and has removed its $36 price target in the wake of discontinuing the SNS-301 program for&...

Karyopharm Announces Expansion Of Royalty Agreement With Healthcare Royalty For Up To $100 Million − Investment Expected to Extend Karyopharm's Cash Runway into the Middle of 2023 - − Agreement Follows a Prior $75M Investment by Healthcare Royalty in Karyopharm...

I list 8 potential reasons the stock is down despite approvals. SIENDO is a major binary event for the stock. The company has adequate cash. For further details see: Karyopharm: Why Is It Down, And What Should Take It Back Up

Photo by ExperienceInteriors/E+ via Getty Images Karyopharm Therapeutics ([[KPTI]] +3.9%) announced the updated results from a Phase I/II study for eltanexor against hypomethylating agent ((HMA)) refractory myelodysplastic syndrome ((MDS)). The presentation at the 2021 American Society o...